Dividends & Buybacks ·
CytoSorbents Corp held its 2026 Annual Meeting of Stockholders on August 13, 2026, where shareholders approved an…
CTSOCytosorbents Corp
CytoSorbents Corp held its 2026 Annual Meeting of Stockholders on August 13, 2026, where shareholders approved an amendment to the Certificate of Incorporation authorizing a reverse stock split at a ratio between 1-for-5 and 1-for-20. The Board retains discretion to determine the exact ratio within this range prior to the one-year anniversary of the meeting. Additionally, five directors were elected, executive compensation was approved on an advisory basis, and WithumSmith+Brown, PC was ratified as the independent auditor. CytoSorbents Corp operates in the medical device industry, specializing in blood purification technologies.